718 related articles for article (PubMed ID: 19117964)
21. A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening.
Kostka B; Para J; Sikora J
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):611-8. PubMed ID: 17890947
[TBL] [Abstract][Full Text] [Related]
22. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity.
Urano T; Nagai N; Matsuura M; Ihara H; Takada Y; Takada A
Thromb Haemost; 1998 Jul; 80(1):161-6. PubMed ID: 9684803
[TBL] [Abstract][Full Text] [Related]
23. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
24. No increased systemic fibrinolysis in women with heavy menstrual bleeding.
Wiewel-Verschueren S; Knol HM; Lisman T; Bogchelman DH; Kluin-Nelemans JC; van der Zee AG; Mulder AB; Meijer K
J Thromb Haemost; 2014 Sep; 12(9):1488-93. PubMed ID: 24954113
[TBL] [Abstract][Full Text] [Related]
25. Bidirectional functions of thrombin on fibrinolysis: Evidence of thrombin-dependent enhancement of fibrinolysis provided by spontaneous plasma clot lysis.
Tomczyk M; Suzuki Y; Sano H; Brzoska T; Tanaka H; Urano T
Thromb Res; 2016 Jul; 143():28-33. PubMed ID: 27179129
[TBL] [Abstract][Full Text] [Related]
26. Acute CO poisoning is associated with impaired fibrinolysis and increased thrombin generation.
Gawlikowski T; Gomolka E; Piekoszewski W; Jawień W; Undas A
Basic Clin Pharmacol Toxicol; 2013 May; 112(5):352-6. PubMed ID: 23228150
[TBL] [Abstract][Full Text] [Related]
27. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
28. Altered clot formation and lysis are associated with increased fibrinolytic activity in ascites in patients with advanced cirrhosis.
Gitto S; Romanelli RG; Cellai AP; Lami D; Vizzutti F; Abbate R; Margheri F; Fibbi G; Del Rosso M; Laffi G
Intern Emerg Med; 2021 Mar; 16(2):339-347. PubMed ID: 32445164
[TBL] [Abstract][Full Text] [Related]
29. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
30. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
31. [Parameters related to fibrinolysis and their meanings].
Urano T; Suzuki Y
Rinsho Byori; 2011 Jul; 59(7):703-8. PubMed ID: 21874797
[TBL] [Abstract][Full Text] [Related]
32. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion.
Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM
J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178
[TBL] [Abstract][Full Text] [Related]
33. A direct oral anticoagulant edoxaban accelerated fibrinolysis via enhancement of plasmin generation in human plasma: dependent on thrombin-activatable fibrinolysis inhibitor.
Morishima Y; Honda Y
J Thromb Thrombolysis; 2019 Jul; 48(1):103-110. PubMed ID: 30972711
[TBL] [Abstract][Full Text] [Related]
34. Unfavorably altered fibrin clot properties in patients with active rheumatoid arthritis.
Kwasny-Krochin B; Gluszko P; Undas A
Thromb Res; 2010 Jul; 126(1):e11-6. PubMed ID: 20471669
[TBL] [Abstract][Full Text] [Related]
35. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
[TBL] [Abstract][Full Text] [Related]
36. Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome.
Martínez-Zamora MA; Creus M; Tassies D; Bové A; Reverter JC; Carmona F; Balasch J
Fertil Steril; 2010 Nov; 94(6):2437-40. PubMed ID: 20378110
[TBL] [Abstract][Full Text] [Related]
37. Laboratory evaluation of patients with undiagnosed bleeding disorders.
Alves GS; Orsi FA; Santiago-Bassora FD; Quaino SK; Montalvão SA; Paula EV; Annichino-Bizzacchi JM
Blood Coagul Fibrinolysis; 2016 Jul; 27(5):500-5. PubMed ID: 26825625
[TBL] [Abstract][Full Text] [Related]
38. Cell-Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis.
Gould TJ; Vu TT; Stafford AR; Dwivedi DJ; Kim PY; Fox-Robichaud AE; Weitz JI; Liaw PC
Arterioscler Thromb Vasc Biol; 2015 Dec; 35(12):2544-53. PubMed ID: 26494232
[TBL] [Abstract][Full Text] [Related]
39. Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: relative contribution of TAFI and PAI-1.
Semeraro F; Giordano P; Faienza MF; Cavallo L; Semeraro N; Colucci M
Thromb Haemost; 2012 Aug; 108(2):311-7. PubMed ID: 22740053
[TBL] [Abstract][Full Text] [Related]
40. Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma.
Nielsen VG
Blood Coagul Fibrinolysis; 2009 Apr; 20(3):191-6. PubMed ID: 19657316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
